Ensayos que prueban un tratamiento · 17 estudios
Aquí se prueba algo nuevo: un medicamento, una pauta o un procedimiento. Si participas, recibes el tratamiento en estudio o el estándar, y el equipo te sigue de cerca.
Prevención de infecciones en pacientes con inmunoglobulinas bajas: inmunoglobulina subcutánea comparada con placebo
The primary purpose of the study is to evaluate whether biweekly administered XEMBIFY® plus Standard Medical Treatment (SMT) over a one-year period will reduce the rate of major bacterial infections per participant per year in B-cell CLL, MM, and NHL participants with hypogammaglobulinemia (HGG) in comparison to the Placebo plus SMT group.
Para: Hypogammaglobulinemia, Bacterial Infections, B-cell Chronic Lymphocytic Leukemia, Multiple Myleoma
6 centros: Brașov · București · Cluj-Napoca · y 3 más
Fase 3Ver la ficha oficial ↗NCT05645107
Título original del registro
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
Leucemia linfocítica crónica o linfoma linfocítico de células pequeñas en recaída: pirtobrutinib
The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of treatment including a covalent Bruton tyrosine kinase (BTK) inhibitor. The purpose of Part 2 of this study is to evaluate pirtobrutinib monotherapy in participants with treatment-naïve CLL/SLL with 17p deletions. Participation in Part 1 is expected to last approximately 3 years. Participation in Part 2 is expected to last up to 2 years.
Para: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
5 centros: Fundeni Clinical Institute, București · Institutul Oncologic Cluj, Cluj-Napoca · Spitalul Clinic Municipal Filantropia Craiova, Craiova · y 2 más
Fase 2Ver la ficha oficial ↗NCT06588478
Título original del registro
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Cánceres de la sangre: nemtabrutinib, un medicamento en estudio
The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Richter's transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström's macroglobulinemia (WM).
Para: Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia
4 centros: Centrul de Diagnostic si Tratament Oncologic Brasov, Brașov · Spitalul Clinic Colțea, București · Institutul Regional de Oncologie Iasi, Iași · y 1 más
Fase 2Ver la ficha oficial ↗NCT04728893
Título original del registro
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Leucemia linfoblástica aguda Ph+ de nuevo diagnóstico: olverembatinib
A global multicenter, open-label, randomized and registrational Phase 3 study to evaluate efficacy and safety of olverembatinib combined with chemotherapy versus investigator's choice of tyrosine kinase inhibitor (TKI) combined with chemotherapy in subjects with newly-diagnosed Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL).
Para: Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
4 centros: București · Cluj-Napoca · Craiova · y 1 más
Fase 3Ver la ficha oficial ↗NCT06051409
Título original del registro
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
Leucemia mieloide aguda de nuevo diagnóstico con mutación NPM1: revumenib añadido a la quimioterapia intensiva
The purpose of this study is to assess if adding revumenib to standard chemotherapy improves outcomes in participants with AML with certain genetic mutations compared to chemotherapy alone. The study will also assess the safety of adding revumenib to chemotherapy.
Para: Acute Myeloid Leukemias
4 centros: București · Cluj-Napoca · Iași · y 1 más
Fase 3Ver la ficha oficial ↗NCT07211958
Título original del registro
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
Leucemia linfocítica crónica o linfoma linfocítico de células pequeñas: APG2575, un medicamento en estudio
This is a global multicenter, open label, randomized, registrational phase III study to investigate the efficacy and safety of lisaftoclax in combination with BTK inhibitors in CLL/SLL patients who previously treated with BTK inhibitors
Para: CLL/SLL
3 centros: București · Cluj-Napoca · Timișoara
Fase 3Ver la ficha oficial ↗NCT06104566
Título original del registro
Global Trial in APG2575 for Patients With CLL/SLL
Leucemia linfocítica crónica o linfoma linfocítico de células pequeñas en recaída: BGB-16673 comparado con pirtobrutinib
The purpose of this study is to evaluate the efficacy and safety of tacabrutideg alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had been previously treated with a covalent Bruton tyrosine kinase inhibitor (cBTKi).
Para: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
3 centros: Coltea Clinical Hospital, București · Institutul Oncologic Prof Dr Ion Chiricuta Cluj Napoca, ClujNapoca · Institutul Regional de Oncologie Iasi, Iași
Fase 3Ver la ficha oficial ↗NCT06973187
Título original del registro
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Leucemia linfocítica crónica sin tratamiento previo: sonrotoclax con zanubrutinib comparado con venetoclax con acalabrutinib
The purpose of this study is to investigate the efficacy and safety of fixed-duration sonrotoclax (also known as BGB-11417) plus zanubrutinib (also known as BGB-3111) (SZ) compared with fixed-duration of venetoclax plus acalabrutinib (AV) in participants with previously untreated chronic lymphocytic leukemia (CLL).
Para: Chronic Lymphocytic Leukemia
3 centros: Coltea Clinical Hospital, București · Institutul Clinic Fundeni, Bucureti · Institutul Oncologic Prof Dr Ion Chiricuta Cluj Napoca, ClujNapoca
Fase 3Ver la ficha oficial ↗NCT07277231
Título original del registro
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Leucemia linfoblástica aguda en niños y adolescentes: trasplante de células madre de un donante
The ALL SCTped 2012 FORUM is a multinational, multi-centre, controlled, prospective phase III study for the therapy and therapy optimisation for children and adolescents with ALL in complete morphological remission (CR, less than 5% bone marrow blasts, no blasts in cerebrospinal fluid, no other extramedullary leukemia), who have an indication for HSCT with a myeloablative conditioning regimen.
The stratification of patients in first and following remissions according to the individual transplantation modalities rests upon an indication for allogeneic HSCT and the availability of a suitable donor within the individual transplantation groups.
Para: Acute Lymphoblastic Leukaemia
2 centros: IInsitutul Clinic Fundeni, Sectia de Transplant Medular, București · University of Medicine and Pharmacy V. BABES, Emergency Children's Hospital LOUIS TURCANU, III. Clinic of Pediatrics , Department of Onco-hematology and Bone Marrow Transplantation, Timișoara
Fase 2Ver la ficha oficial ↗NCT01949129
Título original del registro
Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
Leucemia mieloide aguda o síndrome mielodisplásico con insuficiencia renal: cómo se comporta la decitabina con cedazuridina por vía oral
This is a Phase 1b, multicenter, open-label, PK, and safety study of multiple oral doses of oral decitabine and cedazuridine (formerly known as ASTX727) as a fixed-dose combination of decitabine 35 milligrams (mg) and cedazuridine 100 mg in cancer participants with severe renal impairment and cancer participants with normal renal function as matched control participants. Adult participants with acute myeloid lymphoma (AML), myelodysplastic syndrome (MDS), or solid tumors who are candidates to receive oral decitabine and cedazuridine will be enrolled in this study. Study duration per participant is approximately up to 8 weeks.
Para: Acute Myeloid Leukemia, Myelodysplastic Syndromes
2 centros: Institutul Oncologic Bucuresti - Prof. Dr. Alexandru Trestioreanu, București · Institutul Oncologic Prof. Dr. Ion Chiricuta, Cluj-Napoca
Fase 1Ver la ficha oficial ↗NCT04953897
Título original del registro
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment
Leucemia mieloide aguda o síndrome mielodisplásico con insuficiencia hepática: cómo se comporta la decitabina con cedazuridina por vía oral
This is a Phase 1b, multicenter, open-label, pharmacokinetic (PK), and safety study of multiple oral doses of oral decitabine and cedazuridine (formerly known as ASTX727) as a fixed-dose combination of decitabine 35 milligrams (mg) and cedazuridine 100 mg in cancer participants with moderate and severe hepatic impairment and cancer participants with normal hepatic function as control participants. Participants with severe hepatic impairment will be enrolled only after the safety evaluation of at least 6 participants with moderate hepatic impairment has been determined and supports the enrollment of participants with severe hepatic impairment. Adult participants with acute myeloid lymphoma (AML), myelodysplastic syndrome (MDS), or solid tumors who are candidates to receive oral decitabine and cedazuridine will be enrolled in this study. Study duration is per participant approximately up to 8 weeks.
Para: Acute Myeloid Leukemia, Myelodysplastic Syndromes
2 centros: Institutul Oncologic Bucuresti - Prof. Dr. Alexandru Trestioreanu, București · Institutul Oncologic Prof. Dr. Ion Chiricuta, Cluj-Napoca
Fase 1Ver la ficha oficial ↗NCT04953910
Título original del registro
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment
Leucemia mieloide aguda en torno a un trasplante de células madre: mocravimod como tratamiento añadido y de mantenimiento
This is a multi-center, randomized, double-blinded, placebo controlled trial.
Para: Adult Acute Myeloid Leukemia
2 centros: Institutul Clinic Fundeni, București · Institutul Regional de Oncologie Iasi, - Haematology Department, Iași
Fase 3Ver la ficha oficial ↗NCT05429632
Título original del registro
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
Leucemia mieloide crónica: continuación de asciminib para quienes ya lo recibieron en un estudio
This is a long term safety study for patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment
Para: Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Un centro: Timișoara
Fase 4Ver la ficha oficial ↗NCT04877522
Título original del registro
Asciminib Roll-over Study
Leucemia linfocítica crónica en recaída: venetoclax por vía oral junto con obinutuzumab por vía intravenosa
Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess retreatment with venetoclax-obinutuzumab (VenG) in participants previously treated with fixed duration first-line (IL) therapy of venetoclax in combination with an anti-CD20 antibody +/- X (where X is any additional drug). Adverse events and change in disease activity will be assessed.
Venetoclax is an approved drug for the treatment of CLL. Study doctors put the participants in 1 of 2 groups, called cohorts, based on when symptoms of CLL came back after previous treatment in first-line. Approximately 75 adult participants with CLL who have been treated with venetoclax in combination with an anti-CD20 antibody +/- X will be enrolled in the study in approximately 60 sites worldwide.
Participants will receive intravenous (IV) obinutuzumab + oral venetoclax (VenG) in 28-day cycles for a total of 6 cycles per cohort, followed by 6 to 18 cycles of venetoclax alone, for a total treatment of 12 to 24 cycles, depending on the cohort.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Para: Chronic Lymphocytic Leukemia (CLL)
Un centro: Fundeni Clinical Institute, București
Fase 2Ver la ficha oficial ↗NCT04895436
Título original del registro
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
Leucemia mieloide aguda en recaída o refractaria: un ensayo que compara tratamientos usados en la práctica diaria
This is a multicenter, randomized, open-label, pragmatic low intervention clinical trial comparing high intensity reinduction chemotherapy with low intensity therapies in 1st or 2nd relapse Acute Myeloid Leukemia. The study is funded by European Commission (HORIZON-MISS-2022-CANCER-01-03, Project ID 101104421)
Para: Acute Myeloid Leukemia, Relapse/Recurrence
Un centro: Fundeni Clinical Institute, București
Fase 3Ver la ficha oficial ↗NCT06713837
Título original del registro
IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.
Leucemia mieloide aguda refractaria o en recaída: L-anamicina añadida a citarabina como tratamiento de segunda línea
This pivotal phase 2/3, multi-center, adaptive design study of L-Annamycin for Injection in combination with Cytarabine Injection as second line therapy for remission induction in adult subjects with refractory/relapsed AML is divided into two parts, Part A and Part B.
Para: Acute Myeloid Leukaemia (AML)
Un centro: ARENSIA research clinic at the Oncology Institute "Prof. Dr. Ion Chiricuţă", Cluj-Napoca
Fase 2Ver la ficha oficial ↗NCT06788756
Título original del registro
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
This Phase 3 study in adult participants with newly diagnosed low-risk APL will evaluate the efficacy, safety, and PK of an oral capsule formulation of ATO, in combination with ATRA.
Para: Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia, Acute Promyelocytic Leukemia With PML-RARA, Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA
Un centro: Quetzal Site 19, Cluj-Napoca
Fase 3Ver la ficha oficial ↗NCT07504458
Título completo
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
Fuente: ClinicalTrials.gov, el registro público de la National Library of Medicine de Estados Unidos. Datos obtenidos el 13 oct 2026.
